Table 1.
Baseline characteristics of the HALT-C trial patients.
| Variable† | MDB Absent(n=892) | MDB Present(n=158) | P value‡ |
|---|---|---|---|
|
| |||
| Age (years) | 50.3 ±7.3 | 49.5 ±6.5 | 0.21 |
|
| |||
| Gender: | |||
| Male | 642 (72) | 103(65) | 0.083 |
| Female | 250 (28) | 55 (35) | |
|
| |||
| Race: | |||
| White | 645 (72) | 107(68) | 0.61 |
| Black | 159(18) | 32 (20) | |
| Hispanic | 70(8) | 14(9) | |
| Other | 18(2) | 5(3) | |
|
| |||
| BMI (kg/m2) | 29.6 ±5.4 | 31.3 ±5.5 | <0.001 |
|
| |||
| HOMA-IR | 5.5 ±4.9 | 7.0 ±4.7 | <0.001 |
|
| |||
| Diabetes | 204 (23) | 50 (32) | 0.018 |
|
| |||
| Current drinker | 140 (16) | 33 (21) | 0.10 |
|
| |||
| Current smoker | 263 (30) | 53 (34) | 0.29 |
|
| |||
| HCV Genotype-1 | 840 (94) | 140 (87) | 0.010 |
|
| |||
| Laboratory values | |||
|
| |||
| Albumin (g/dL) | 3.9 ±0.4 | 3.7 ±0.4 | <0.001 |
|
| |||
| Total bilirubin (mg/dL) | 0.8 ±0.4 | 0.8 ±0.4 | 0.081 |
|
| |||
| Platelet (K/mm3) | 168 ±65 | 148 ±66 | <0.001 |
|
| |||
| INR | 1.0 ±0.1 | 1.1 ±0.1 | 0.029 |
|
| |||
| AFP (ng/mL) | 15.5 ±26.8 | 28.2 ±39.2 | <0.001 |
|
| |||
| AST/ALT ratio | 0.9 ±0.3 | 0.9 ±0.3 | 0.006 |
|
| |||
| Ferritin (ng/mL) | 344 ±398 | 443 ±446 | 0.009 |
|
| |||
| Histology | |||
|
| |||
| Biopsy length (cm) | 1.8 ± 0.8 | 1.9 ± 1.3 | 0.43 |
|
| |||
| Fragmented biopsy | 211 (24) | 36 (23) | 0.81 |
|
| |||
| Fibrosis | 4.0 ±1.3 | 4.6 ±1.2 | <0.001 |
| %Bridging fibrosis (3–4) | 62.5 | 41.1 | |
| %Crrihosis (5–6) | 37.5 | 58.9 | |
|
| |||
| Steatosis (0–4) | 1.3 ±0.9 | 2.0 ±0.9 | <0.001 |
|
| |||
| Inflammation (0–12) | 7.4 ±2.1 | 8.4 ±1.9 | <0.001 |
|
| |||
| Zone-3 pericellular fibrosis (0–2) | 0.37 ±0.6 | 0.66 ±0.7 | <0.001 |
|
| |||
| Iron grade (0–3) | 0.51 ±0.70 | 0.35 ±0.61 | 0.008 |
†
Data reported as mean ±standard deviation (mean ±S.D.) for continuous variables and n (%) for categorical variables.
‡
t-test used for continuous variables; chi-square test for categorical variable.